Without descending into undo speculation I choose to emphasize there is a reason why they submitted to participate in the MASH conference in the first place and that would be based on positive contributory data emphasizing Leronlimab’s impact on the disease state.

Maybe whatever data lens said let’s do it is also seeing a fuller picture needing time for a more robust analysis. If the focal point of the lens is on the follow on SMC murine studies which took a poke at semaglutide and a broader understanding of fibrosis reversal from other causes beyond NASH such as viral origin the implications might warrant sufficient pause to ensure the story being told makes for a richer read. Maybe the audience got bigger…

I suspect we will know soon.